Literature DB >> 30429952

2-Aminoadipic Acid-C(O)-Glutamate Based Prostate-Specific Membrane Antigen Ligands for Potential Use as Theranostics.

Ryo Nakajima1, Zora Nováková2, Werner Tueckmantel3, Lucia Motlová2, Cyril Bařinka2, Alan P Kozikowski3.   

Abstract

The design and synthesis of prostate specific membrane antigen (PSMA) ligands derived from 2-aminoadipic acid, a building block that has not previously been used to construct PSMA ligands, are reported. The effects of both the linker length and of an N-substituent of our PSMA ligands were probed, and X-ray structures of five of these ligands bound to PSMA were obtained. Among the ligands disclosed herein, 13b showed the highest inhibitory activity for PSMA. As ligand 13b can readily be radiolabeled since its fluorine atom is adjacent to the nitrogen atom of its pyridine ring, the use of this and related compounds as theranostics can be pursued.

Entities:  

Year:  2018        PMID： 30429952      PMCID： PMC6231180          DOI： 10.1021/acsmedchemlett.8b00318

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  31 in total

1.  Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.

Authors:  Jan Tykvart; Jiří Schimer; Andrej Jančařík; Jitka Bařinková; Václav Navrátil; Jana Starková; Karolína Šrámková; Jan Konvalinka; Pavel Majer; Pavel Šácha
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

2.  A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.

Authors:  Saurabh Aggarwal; Pratap Singh; Ozlem Topaloglu; John T Isaacs; Samuel R Denmeade
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

3.  A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.

Authors:  Michael D Henry; Shenghua Wen; Matthew D Silva; Sudeep Chandra; Mark Milton; Peter J Worland
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

4.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

5.  PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.

Authors:  Ursula Elsässer-Beile; Gerald Reischl; Stefan Wiehr; Patrick Bühler; Philipp Wolf; Karen Alt; John Shively; Martin S Judenhofer; Hans-Jürgen Machulla; Bernd J Pichler
Journal:  J Nucl Med       Date:  2009-03-16       Impact factor: 10.057

6.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.

Authors:  Cyril Barinka; Klara Hlouchova; Miroslava Rovenska; Pavel Majer; Miroslawa Dauter; Niyada Hin; Yao-Sen Ko; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2008-01-05       Impact factor: 5.469

7.  Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies.

Authors:  Haofan Wang; Youngjoo Byun; Cyril Barinka; Mrudula Pullambhatla; Hyo-Eun C Bhang; James J Fox; Jacek Lubkowski; Ronnie C Mease; Martin G Pomper
Journal:  Bioorg Med Chem Lett       Date:  2009-10-24       Impact factor: 2.823

8.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

9.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.

Authors:  Zora Novakova; Jiri Cerny; Cindy J Choy; Jessie R Nedrow; Joeseph K Choi; Jacek Lubkowski; Clifford E Berkman; Cyril Barinka
Journal:  FEBS J       Date:  2015-11-05       Impact factor: 5.542

10.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Authors:  Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-26       Impact factor: 9.236
View more
  2 in total

1.  Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.

Authors:  Jakub Ptacek; Dong Zhang; Liming Qiu; Sven Kruspe; Lucia Motlova; Petr Kolenko; Zora Novakova; Shambhavi Shubham; Barbora Havlinova; Petra Baranova; Shi-Jie Chen; Xiaoqin Zou; Paloma Giangrande; Cyril Barinka
Journal:  Nucleic Acids Res       Date:  2020-11-04       Impact factor: 16.971

Review 2.  PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.

Authors:  Sashi Debnath; Ning Zhou; Mark McLaughlin; Samuel Rice; Anil K Pillai; Guiyang Hao; Xiankai Sun
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.